Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+34.28%
+6.50%
-6.76%
+1.93%
+1.43%
MNPR
Monopar Therapeutics
$99.39
Login to see Monopar Therapeutics (MNPR) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Upgraded on attractively valued
Outperform the market
Chart
$44.93 (+121.21%)
$43.73 (+127.28%)
$39.55 (+151.30%)
$5.25 (+1793.14%)
MNPR has Extreme Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
Low volume
High volatilty
MNPR overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Outperform the market
MNPR Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
MNPR Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayMNPR Earnings
The TTM reflects 12-month period, providing review of MNPR financial performance.
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
What is MNPR current stock price?
What are MNPR stock strengths?
What risks are associated with MNPR stock?
When is MNPR next earnings report?
What is MNPR market cap and volume?
What is MNPR's current Stock IQ?
Should I buy MNPR stock right now?
Is MNPR a Strong Buy right now?
What does a 'Strong Buy' rating mean for MNPR?
What does a 'Strong Sell' rating mean for MNPR?
What factors influence MNPR's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+34.28%
+6.50%
-6.76%
+1.93%
+1.43%
MNPR
Monopar Therapeutics
Current Price
$99.39
Stock Insights
Strengths
Upgraded on attractively valued
Outperform the market
Login to unlock Monopar Therapeutics (MNPR) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$44.93 (+121.21%)
$43.73 (+127.28%)
$39.55 (+151.30%)
$5.25 (+1793.14%)
MNPR Analysts Opinion
MNPR Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Outperform the market
MNPR Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
MNPR Street view is extremely bullish and have positive views on the near-term outlook
MNPR has Extreme Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
Low volume
High volatilty
Average key support and resistance price levels.
Login to displayMNPR Earnings
The TTM data reflects the most recent 12-month period, providing overview of MNPR financial performance.
MNPR Financial Health
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
MNPR Latest Analysis
Oppenheimer Maintains Monopar Therapeutics (MNPR) Outperform Recommendation. Fintel reports that on October 2 2025 Oppenheimer maintained coverage of Monopar Therapeutics (NasdaqCM:MNPR) with a Outperform recommendation. Analyst Price Forecast Suggests 2.02% Upside
Fri Oct 3, 2025
HC Wainwright & Co. Maintains Monopar Therapeutics (MNPR) Buy Recommendation. Fintel reports that on September 29 2025 HC Wainwright &. Co. maintained coverage of Monopar Therapeutics (NasdaqCM:MNPR) with a Buy recommendation. Analyst Price Forecast Suggests 10.18% Upside
Tue Sep 30, 2025
Monopar Therapeutics (MNPR) Price Target Increased by 18.34% to 99.28. The average one-year price target for Monopar Therapeutics (NasdaqCM:MNPR) has been revised to $99.28 / share. This is an increase of 18.34% from the prior estimate of $83.90 dated September 10 2025. The price target is an average of many targets provided by
Tue Sep 30, 2025
Piper Sandler Maintains Monopar Therapeutics (MNPR) Overweight Recommendation. Fintel reports that on September 25 2025 Piper Sandler maintained coverage of Monopar Therapeutics (NasdaqCM:MNPR) with a Overweight recommendation. Analyst Price Forecast Suggests 7.61% Upside
Fri Sep 26, 2025
Chardan Capital Maintains Monopar Therapeutics (MNPR) Buy Recommendation. Fintel reports that on September 25 2025 Chardan Capital maintained coverage of Monopar Therapeutics (NasdaqCM:MNPR) with a Buy recommendation. Analyst Price Forecast Suggests 14.86% Upside
Thu Sep 25, 2025
BTIG Maintains Monopar Therapeutics (MNPR) Buy Recommendation. Fintel reports that on September 25 2025 BTIG maintained coverage of Monopar Therapeutics (NasdaqCM:MNPR) with a Buy recommendation. Analyst Price Forecast Suggests 14.86% Upside
Thu Sep 25, 2025
Monopar Announces Pricing Of $19.2 Mln Public Offering Of Common Stock . (RTTNews) - Monopar Therapeutics Inc. (MNPR) announced the pricing of an underwritten registered offering involving 1.03 million shares of its common stock at $67.67 per share. In addition certain investors will receive pre-funded warrants instead of common stock allowing them
Wed Sep 24, 2025
Why Monopar Therapeutics A Top 1% Biotech Stock Just Surged Into A Breakout. Monopar Therapeutics unveiled promising results Monday from three key studies leading the top 1% biotech stock to break out of a cup base.The post Why Monopar Therapeutics A Top 1% Biotech Stock Just Surged Into A Breakout appeared first on Investor'.s Business Daily.
Mon Sep 15, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
MNPR Stock trends
MNPR Stock performance
MNPR Stock analysis
MNPR investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings